Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 16/10/2019
SIETES contiene 92824 citas

 
 
 1 a 20 de 792 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Ioannidis JPA. The proposal to lower P value thresholds to .005. JAMA 2018;319:1429-30. [Ref.ID 102667]
2. Cita con resumen
VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the e-value . Ann Intern Med 2017;167:268-74. [Ref.ID 102038]
3. Cita con resumen
Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]
4. Cita con resumen
Moore TJ, Furberg CD. Electronic health data for postmarket surveillance: a vision not realized. Drug Saf 2015;38:601-10. [Ref.ID 99852]
5. Cita con resumen
Haukoos JS, Lewis RJ. The propensity score. JAMA 2015;314:1637-8. [Ref.ID 99568]
6. Cita con resumen
7. Cita con resumen
Murad MH, Montori VM. Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA 2013;309:2217-8. [Ref.ID 95591]
8. Cita con resumen
Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:15. [Ref.ID 95533]
9. Cita con resumen
Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, for the CONSORT PRO Group. Reporting on patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA 2013;309:814-22. [Ref.ID 94991]
11. Cita con resumen
Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ. When is a further clinical trial justified?. BMJ 2012;345:19. [Ref.ID 94137]
12.Tiene citas relacionadas Cita con resumen
Anónimo. My experience in the drug industry. BMJ 2012;344:28. [Ref.ID 93249]
13.Tiene citas relacionadas Cita con resumen
Evans SJW. An agenda for UK clinical pharmacology: pharmacoepidemiology. Br J Clin Pharmacol 2012;73:973-8. [Ref.ID 93098]
14. Cita con resumen
Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011;342:964-7. [Ref.ID 90697]
15. Cita con resumen
Ioannidis J, Karassa F. The need to consider the wider agenda in systematic reviews and meta-analyses. BMJ 2010;341:762-5. [Ref.ID 89476]
16. Cita con resumen
Hutcheon JA, Chiolero A, Hanley JA. Random measurement error and regression dilution bias. BMJ 2010;340:1402-6. [Ref.ID 88747]
18. Cita con resumen
Boutron I, Dutton S, Ravaud P, Altman DG. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64. [Ref.ID 88510]
19. Cita con resumen
Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, Heels Ansdell D, Walter SD, Guyatt GH, and the STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects. Systematic review and meta-regression analysis. JAMA 2010;303:1180-7. [Ref.ID 88155]
20.Enlace a cita original
Sekula P, Caputo A, Dunant A, Roujeau J-C, Mockenhaupt M, Sidoroff A, Schumacher M. An application of propensity score methods to estimate the treatment effect of corticosteroids in patients with severe cutaneous adverse reactions. Pharmacoepidemiol Drug Saf 2010;19:10-8. [Ref.ID 87581]
Seleccionar todas
 
 1 a 20 de 792 siguiente >>